Last but not least, the present study validated that GRHL2 activated MAPK signalling pathway and exacerbated liver fibrosis and intestinal mucosal barrier dysfunction in NAFLD mice. Here, GRHL2 is linked to metabolic dysfunction-associated steatotic liver disease.